| | | | | |

Effect of Chemotherapy on Immunotherapy for Mesothelioma

ByAlex Strauss
effect of chemotherapy on immunotherapy

Belgian scientists say they are still not sure about the effect of chemotherapy on immunotherapy for mesothelioma. They reached that conclusion after testing several different chemotherapy drugs on mesothelioma cells in the lab.

The combination of chemotherapy and immunotherapy is “chemoimmunotherapy”. It aims to harness the unique powers of each treatment approach. A meta-analysis last May called chemoimmunotherapy the “next frontier” in mesothelioma treatment. 

But the new Belgian study on the effect of chemotherapy on immunotherapy highlights how much doctors still do not know about the combo.

Immune Checkpoints Are the Key

When it is working properly, the immune system is supposed to find and kill cancer cells before they become mesothelioma tumors. But mesothelioma cells can hide from the immune system. This makes malignant mesothelioma especially deadly. 

Mesothelioma cells hide themselves using immune checkpoints. The proteins PD-1, LAG-3, and TIM-3 are examples of immune checkpoints.

New drugs called immune checkpoint inhibitors block these proteins and unmask mesothelioma cells. Keytruda (pembrolizumab) is one immune checkpoint inhibitor. Opdivo is another one.

These drugs leave mesothelioma cells more vulnerable to immune system attack. They can also make them more susceptible to the effect of chemotherapy on immunotherapy.

Evaluating the Effect of Chemotherapy on Immunotherapy

The primary treatment for mesothelioma is chemotherapy. But it usually only extends mesothelioma survival for a few months. 

Doctors know that immunotherapy and chemotherapy drugs affect each other. But they still do not know exactly how. That makes it hard to design the best mesothelioma treatment protocol. 

Researchers at the University of Antwerp tested three of the most common mesothelioma chemotherapy drugs. The goal was to measure the effect of chemotherapy on immunotherapy markers like immune checkpoints.

Researchers applied cisplatin, pemetrexed (Alimta), and oxaliplatin to healthy cells and mesothelioma cells. Of the three drugs, cisplatin had the biggest impact on the immunity markers.

“Cisplatin might be a promising treatment to combine with immune checkpoint blocking antibodies since our MPM cell lines were most susceptible to this stand-alone treatment,” writes lead author Elly Marcq. 

The other two drugs either downregulated immune checkpoints or did not affect them at all. This was true in both the mesothelioma cells and the healthy cells. 

Unfortunately, the team could find “no clear trend” in the effect of chemotherapy on immunotherapy. They conclude that the combination should be studied more extensively. 

In the meantime, scientists continue to develop new immunotherapy drugs. The best way for mesothelioma patients to access immunotherapy is to join a clinical trial. 

Sources:

Marcq, E, et al, “Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression”, August 26, 3019, International Journal of Molecular Science, https://www.mdpi.com/1422-0067/20/17/4182

Nowak, AK, “Immune checkpoint inhibition for the treatment of mesothelioma”, May 2, 2019, Expert Opinions in Biological Therapy, Epub ahead of print, https://www.tandfonline.com/doi/abs/10.1080/14712598.2019.1606209?journalCode=iebt20

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Mesothelioma Still Rising Despite Ban in Ireland
|

Mesothelioma Still Rising Despite Ban in Ireland

ByAlex Strauss

A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Website Aims to Protect Homeowners from Mesothelioma
|

Website Aims to Protect Homeowners from Mesothelioma

ByAlex Strauss

Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

Ape Virus Shrinks Mesothelioma Tumors in Lab
|

Ape Virus Shrinks Mesothelioma Tumors in Lab

ByAlex Strauss

A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…